Tatva Chintan Pharma Chem Reports Q2FY27 EBITDA Growth
ICICI Securities reports EBITDA rose 26% QoQ and 83.3% YoY to INR 407mn; revenue increased 75.9% YoY, with strength particularly in SDA.
ICICI Securities’ research report said Tatva Chintan Pharma Chem (TATVA) continued its strong EBITDA growth in Q2FY27, with EBITDA rising 26% QoQ and 83.3% YoY to INR 407mn. Revenue increased 75.9% YoY, supported by solid performance across segments, particularly SDA. EBITDA margin held…